Pfizer Shares Slip Nearly 2% After Sigvotatug Vedotin Misses Survival Endpoint in 703-Patient Trial
PFE•Pfizer’s sigvotatug vedotin failed to meet the primary overall survival endpoint against docetaxel in a 703-patient non-squamous NSCLC trial, pushing shares down nearly 2% after-hours. In the prespecified second-line subgroup (~two-thirds of patients), it showed favorable signals in overall survival, progression-free survival and response rate with a manageable safety profile.
1. Phase III Trial Outcome
In the SigVie-002 study of 703 patients with previously treated metastatic non-squamous NSCLC, sigvotatug vedotin did not achieve a statistically significant improvement in overall survival versus docetaxel, resulting in failure to meet the trial’s primary endpoint.
2. Second-Line Subgroup Analysis
Within the prespecified second-line subgroup—comprising approximately two-thirds of enrolled patients—the drug demonstrated positive trends in overall survival, progression-free survival and objective response rate, alongside a manageable safety profile consistent with earlier clinical data.
3. Market Reaction and Pipeline Impact
Shares declined nearly 2% in after-hours trading following the announcement. Sigvotatug vedotin, part of Pfizer’s $43 billion Seagen acquisition and its plan for eight potential cancer breakthroughs by 2030, will be pivotal to the company’s oncology valuation moving forward.
